Thryvtrx
5 known investors
Find your way into Thryvtrx
2,287 people in our graph share verified history with the Thryvtrx team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Matt Killeen · together at Stanford University (overlapped)
knows the team · via Chief
×6knows the team · via Stanford University
knows the team · via University of California, Davis
knows the team · via Indiana University Bloomington
×2knows the team · via University of Leeds
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
Founders & leadership
PF
Paul F. TruexinChairman of the Board & Chief Executive OfficerPaul Truex is CEO and Chairman of Thryv Therapeutics, a clinical-stage biotech developing SGK1 inhibitors for genetic arrhythmia syndromes and cardiometabolic diseases. He previously founded Anthera Pharmaceuticals and Peninsula Pharmaceuticals, and has held business development roles at Eli Lilly including involvement with the Lilly ICOS joint venture; he holds an MBA from Indiana University and a BA in Economics from the University of Waterloo.
DO
Debra OdinkinPresident & Chief Development Officer
AS
Amy SehnertinChief Medical OfficerAmy Sehnert is Chief Medical Officer at Thryv Therapeutics, a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and cardiometabolic diseases. She is a physician-scientist with experience in clinical program development, regulatory approvals, and product launches across cardiology, genetics, maternal-fetal medicine, and oncology.
MK
Matt KilleeninChief Business OfficerMatt Killeen holds a PhD in cardiac electrophysiology from Cambridge and has led R&D and strategic roles across multiple biotech companies, including BioMarin (where he built a cardiovascular disease portfolio), Renovacor (as Chief Scientific Officer, through its acquisition by Rocket Pharmaceuticals in 2022), and TikkunLev Therapeutics (as President). He is currently Chief Business Officer at Thryv Therapeutics, overseeing corporate development and cardiometabolic pipeline strategy.
Board
SD
Saumya DasChief Scientific Advisor
Investors · 5
Competitors · 2
by search overlap
Medscape68 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
UPMC46 shared keywordsUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Companies competing with Thryvtrx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Thryvtrx do?
- Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
- Who are Thryvtrx's investors?
- Thryvtrx's investors include Lumira Ventures, adMare BioInnovations, Amzak Health, CTI Life Sciences Fund L.P., Fonds de solidarité FTQ.